Hyloris Finds A Partner In China For Maxigesic IV Amid Business Disruptions
Intravenous Non-Opioid Pain Treatment Launched In More Than 30 Countries
Hyloris recognized that the suspension of its shares as part of a broader business fallout has “created uncertainty and temporarily impacted management and organizational focus,” as it got another commercial deal over the line for its Maxigesic IV (paracetamol/ibuprofen) solution for infusion.
